Akebia Ther (AKBA)vsViatris Inc (VTRS)
AKBA
Akebia Ther
$0.50
-13.20%
HEALTHCARE · Cap: $195.78M
VTRS
Viatris Inc
$20.67
-1.85%
HEALTHCARE · Cap: $23.90B
Smart Verdict
WallStSmart Research — data-driven comparison
Viatris Inc generates 6623% more annual revenue ($14.73B vs $219.06M). VTRS leads profitability with a -4.1% profit margin vs -13.5%. VTRS earns a higher WallStSmart Score of 40/100 (D).
AKBA
Avoid24
out of 100
Grade: F
VTRS
Hold40
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AKBA.
Margin of Safety
-81.4%
Fair Value
$8.89
Current Price
$20.67
$11.78 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -74.9% — below average capital efficiency
Expensive relative to growth rate
ROE of -2.9% — below average capital efficiency
Revenue declined 0.3%
Earnings declined 70.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : AKBA
AKBA has a balanced fundamental profile.
Bull Case : VTRS
The strongest argument for VTRS centers on Price/Book.
Bear Case : AKBA
The primary concerns for AKBA are EPS Growth, Market Cap, Piotroski F-Score. Debt-to-equity of 2.16 is elevated, increasing financial risk.
Bear Case : VTRS
The primary concerns for VTRS are PEG Ratio, Return on Equity, Revenue Growth.
Key Dynamics to Monitor
VTRS carries more volatility with a beta of 0.87 — expect wider price swings.
VTRS is growing revenue faster at -0.3% — sustainability is the question.
VTRS generates stronger free cash flow (329M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
VTRS scores higher overall (40/100 vs 24/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Akebia Ther
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of kidney therapies for patients with kidney disease. The company is headquartered in Cambridge, Massachusetts.
Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?